ESC & iPSC News Volume 6.00 | Jan 4 2011

INDUSTRY NEWS

Advanced Cell Technology and The Roslin Institute Announce Agreement for Storage and Distribution of Embryonic Stem Cells Using ACT’s Blastomere Technology
Advanced Cell Technology, Inc. (ACT) announced that it has entered into a Memorandum of Understanding with Roslin Cells LTD of Scotland, in which the two companies contemplate a definitive collaboration agreement in the near future. [Advanced Cell Technology, Inc. Press Release]

Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
Transposagen Biopharmaceuticals, Inc. announced that it has entered into a non-exclusive license agreement with Cellular Dynamics International, the world’s largest producer of human induced pluripotent stem cell lines and tissue cells, for drug discovery and safety. [Transposagen Biopharmaceuticals, Inc. Press Release]

ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes
ReproCELL, Inc. announced that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation, which could offer new hepatocyte derived from human induced pluripotent stem (iPS) cells used for an effective in vitro drug screening for hepatic toxicity and liver metabolism. [PR Newswire]

Advanced Cell Technology Secures $25 Million Funding Commitment
Advanced Cell Technology, Inc. announced that it has entered into a $25 million non-convertible stock purchase agreement with Socius CG II, Ltd., a subsidiary of Socius Capital Group. [Advanced Cell Technology, Inc. Press Release]

Advanced Cell Technology Receives FDA Clearance for Clinical Trials Using Embryonic Stem Cells to Treat Age-Related Macular Degeneration
Advanced Cell Technology, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application to treat Dry Age-Related Macular Degeneration using retinal pigment epithelial cells derived from human embryonic stem cells. [Advanced Cell Technology, Inc. Press Release]

Aldagen Announces FDA Clearance of IND to Begin Phase II Study in Ischemic Stroke with Regenerative Cell Therapy
Aldagen, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to conduct a clinical trial using Aldagen’s ALD-401, a unique stem cell population, for the treatment of stroke patients. [Market Wire]